Research programme: corticosteroid derivatives - Aqualis

Drug Profile

Research programme: corticosteroid derivatives - Aqualis

Alternative Names: CP-4112; CP-4114; CP-4166

Latest Information Update: 07 Nov 2013

Price : $50

At a glance

  • Originator Clavis Pharma
  • Developer Aqualis
  • Class Fluorinated steroids; Pregnadienetriols
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 09 Oct 2013 Clavis Pharma is now called Aqualis
  • 29 Aug 2013 Discontinued - Preclinical for Inflammation in Norway (unspecified route)
  • 16 Mar 2009 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top